#biotech #neurology #neurologicaldisorders #Leqembi #lecanemab #NICEdraftguidance #NICE
#EisaiEuropeLtd #Eisai #BiogenIdecLtd #Biogen #MHRA #dementia #Alzheimersdisease #AD #costeffectiveness #NHSEngland #NHSWales #patientaccess #reimbursement #valueofmedicines
pharmatimes.com/news/leqembi...
#EisaiEuropeLtd #Eisai #BiogenIdecLtd #Biogen #MHRA #dementia #Alzheimersdisease #AD #costeffectiveness #NHSEngland #NHSWales #patientaccess #reimbursement #valueofmedicines
pharmatimes.com/news/leqembi...
Leqembi enters second consultation period following NICE draft guidance update - PharmaTimes
NICE convenes third committee meeting for additional appraisal consideration
pharmatimes.com
March 6, 2025 at 12:15 PM
#NHSdiabetesstrategy #GLP1 #NHS #type2diabetes #personalisedapproach #expandedaccess #GLP1agonisttherapies #NHScosts #Individualisedcare #NICEdraftguidance #NICE #SGLT2inhibitors #GLP1receptoragonists #NICEguidance #NHS10Yearplan #patientadvocacy #DiabetesUK
pharmaphorum.com/news/new-nhs...
pharmaphorum.com/news/new-nhs...
New NHS diabetes strategy could raise GLP-1 drug use
New guidelines on NHS management of type 2 diabetes will introduce a more personalised approach that could see expanded access to drug treatments
pharmaphorum.com
September 3, 2025 at 8:20 AM